Relationship of plasma matrix metalloproteinase-9 and hematoma expansion in acute hypertensive cerebral hemorrhage

Int J Neurosci. 2016;126(3):213-8. doi: 10.3109/00207454.2015.1007372. Epub 2015 Aug 18.

Abstract

In the present study, we aimed to investigate the relationship of plasma matrix metalloproteinase-9 (MMP-9) and hematoma expansion (HE) in acute hypertensive cerebral hemorrhage (AHCH) (HE-in-AHCH). Patients with hypertensive cerebral hemorrhage, confirmed by head computed tomography (CT) within 12 h of onset, were prospectively collected. Venous blood was sampled within 4 h of the confirmation to determine the serum MMP-9 concentration. The blood pressure and National Institute of Health Stroke Score of the patients were recorded on hospital admission. CT re-scanning was performed within 42-54 h of the first head CT examination or immediately after worsening of the patients' consciousness disorder. The relationship between MMP-9 level and HE was analyzed. A total of 186 patients were included. Of these patients, 41 had HE (22.0%). Multivariate logistic regression analysis showed that, in addition to the short interval between onset and the first CT examination, and the irregularity of hematoma shape, increasing MMP-9 level was an independent risk factor for HE-in-AHCH (OR value = 15.65, 95% CI: 5.30-46.15). Moreover, increasing plasma MMP-9 level was identified as an independent risk factor in patients with HE-in-AHCH.

Keywords: hematoma expansion; hypertensive; intracranial hemorrhage; matrix metalloproteinase-9.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Brain / pathology*
  • Cerebral Hemorrhage / blood*
  • Cerebral Hemorrhage / complications
  • Cerebral Hemorrhage / pathology
  • Female
  • Hematoma / blood*
  • Hematoma / complications
  • Hematoma / pathology
  • Humans
  • Intracranial Hemorrhage, Hypertensive / blood*
  • Intracranial Hemorrhage, Hypertensive / complications
  • Intracranial Hemorrhage, Hypertensive / pathology
  • Male
  • Matrix Metalloproteinase 9 / blood*
  • Middle Aged
  • Risk Factors

Substances

  • Matrix Metalloproteinase 9